This evidence provides the basis for future controlled trials focused on dry eye outcomes and biomarker-driven (e.g., MMP-9) patient selection to explore ACXL as an adjunctive therapy in DED both in children and adults, beyond KC. The gene discussed is MMP9; the disease is keratoconus.